1. Pisani P., Parkin D.M., Bray F., Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:18–29.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
3. Kuper H., Adami H.O., Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med. 2000;248:171–183.
4. Ohshima H., Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994;305:253–264.
5. Ellermann V., Bang O. Experimentelle Leukamie bei Huhnern. Zentralbl Bakteriol. 1908;46:595–609.
6. Rous P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med. 1911;13:397–411.
7. Shope R.E., Hurst E.W. Infectious papillomatosis of rabbits; with a note on the histopathology. J Exp Med. 1933;58:607–624.
8. Rous P., Beard J.W. Carcinomatous changes in virus-induced papillomas of rabbits. Proc Soc Exp Biol Med. 1935;32:578–580.
9. Gross L. Pathogenic properties, and “vertical” transmission of the mouse leukemia agent. Proc Soc Exp Biol Med. 1951;62:523–548.
10. Gross L. A filtrable agent, recovered from Akr leukemia extracts, causing salivary gland carcinomas in C3H mice. Proc Soc Exp Biol Med. 1953;83:414–421.
11. Stewart S.E. Leukemia in mice produced by a filterable agent present in AKR leukemic tissues with notes on a sarcoma produced by the same agent. Anat Rev. 1953;117:532.
12. Doorbar J., Quint W., Banks L. et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(suppl 5):F55–F70.
13. Howley P.M., Schiller J.T., Lowy D.R. Papillomaviruses. In: Knipe D.M., Howley P.M., eds. Fields Virology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013:1662–1703.
14. Rous P., Kidd J.G. The carcinogenic effect of a virus upon tarred skin. Science. 1936;83:468–469.
15. Kidd J.G., Rous P. Effect of the papillomavirus (Shope) upon tar warts of rabbits. Proc Soc Exp Biol Med. 1937;37:518–520.
16. Jarrett W.F.H., McNeil P.E., Grimshaw W.I.R., Selman I.E., McIntyre W.I.M. High incidence area of cattle cancer with a possible interaction between an environmental carcinogen and a papillomavirus. Nature. 1978;274:215–217.
17. de Martel C., Ferlay J., Franceschi S. et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–615.
18. Freeman H., Wingrove B. Excess Cervical Cancer Mortality: a Marker for Low Access to Health Care in Poor Communities. Rockville, Md: National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005: NIH Pub. No. 05–5282.
19. Meisels A., Fortin R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol. 1976;20:505–509.
20. Durst M., Gissmann L., Idenburg H., zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983;80:3812–3815.
21. Boshart M., Gissman L., Ikenberg H., Kleinheinz A., Scheurlen W., zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984;3:1151–1157.
22. Munoz N., Bosch F.X., de Sanjose S. et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527.
23. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550–560.
24. White E.A., Howley P.M. Proteomic approaches to the study of papillomavirus-host interactions. Virology. 2013;435:57–69.
25. White A., Livanos E.M., Tlsty T.D. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev. 1994;8:666–677.
26. Munger K., Baldwin A., Edwards K.M. et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78:11451–11460.
27. Korzeniewski N., Spardy N., Duensing A., Duensing S. Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett. 2011;305:113–122.
28. Duensing S., Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002;62:7075–7082.
29. Münger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63:4417–4421.
30. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989;8:3905–3910.
31. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76–79.
32. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991;10:4129–4135.
33. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquination of p53. Cell. 1993;75:495–505.
34. Pihan G.A., Wallace J., Zhou Y., Doxsey S.J. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003;63:1398–1404.
35. Gardiol D., Kuhne C., Glaunsinger B., Lee S.S., Javier R., Banks L. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene. 1999;18:5487–5496.
36. Nakagawa S., Huibregtse J.M. Human scribble (vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol. 2000;20:8244–8253.
37. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 1996;380:79–81.
38. Kiyono T., Foster S.A., Koop J.I., McDougall J.K., Galloway D.A., Klingelhutz A.J. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 1998;396:84–88.
39. Winkelstein W.J. Smoking and cancer of the uterine cervix. Am J Epidemiol. 1977;106:257–259.
40. Yokota J., Tsukada Y., Najajima T. et al. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res. 1989;49:3598–3601.
41. Ohta M., Inoue H., Cotticelli M.G. et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587–597.
42. Huang L.W., Chao S.L., Chen T.J. Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. Gynecol Oncol. 2003;90:331–337.
43. Yang Y.X., Yang A.H., Yang Z.J., Wang Z.R., Xia X.H. Involvement of tumor suppressor in lung cancer 1 gene expression in cervical carcinogenesis. Int J Gynecol Cancer. 2006;16:1868–1872.
44. Backes D.M., Kurman R.J., Pimenta J.M., Smith J.S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20:449–457.
45. Smith J.S., Backes D.M., Hoots B.E., Kurman R.J., Pimenta J.M. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol. 2009;113:917–924.
46. Grussendorf-Conen E.I. Anogenital premalignant and malignant tumors (including Buschke-Lowenstein tumors). Clin Dermatol. 1997;15:377–388.
47. Masih A.S., Stoler M.H., Farrow G.M., Wooldridge T.N., Johansson S.L. Penile verrucous carcinoma: a clinicopathologic, human papillomavirus typing and flow cytometric analysis. Mod Pathol. 1992;5:48–55.
48. Williams A.B., Darragh T.M., Vranizan K., Ochia C., Moss A.R., Palefsky J.M. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol. 1994;83:205–211.
49. Park I.U., Palefsky J.M. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr Infect Dis Rep. 2010;12:126–133.
50. Chaturvedi A.K., Engels E.A., Pfeiffer R.M. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–4301.
51. Jordan R.C., Lingen M.W., Perez-Ordonez B. et al. Validation of methods for oropharyngeal cancer HPV status determination in U.S. cooperative group trials. Am J Surg Pathol. 2012;36:945–954.
52. Ang K.K., Harris J., Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
53. Ramqvist T., Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res. 2011;31:1515–1519.
54. Orth G. Epidermodysplasia verruciformis. In: Howley P.M., ed. The Papovaviridae: Volume 2. The Papillomaviruses. New York: Plenum Press; 1987:199–243.
55. Ramoz N., Taieb A., Rueda L.A. et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J Invest Dermatol. 2000;114:1148–1153.
56. Ramoz N., Rueda L.A., Bouadjar B., Montoya L.S., Orth G., Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet. 2002;32:579–581.
57. Leigh I.M., Buchanan J.A., Harwood C.A., Cerio R., Storey A. Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S49–S57.
58. Padlewska K., Ramoz N., Cassonnet P. et al. Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis. J Invest Dermatol. 2001;117:935–942.
59. Iftner T., Bierfelder S., Csapo Z., Pfister H. Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J Virol. 1988;62:3655–3661.
60. Orth G. Human papillomaviruses associated with epidermodysplasia verruciformis in non-melanoma skin cancers: guilty or innocent? J Invest Dermatol. 2005;125:xii–xiii.
61. Grulich A.E., van Leeuwen M.T., Falster M.O., Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.
62. Feltkamp M.C., de Koning M.N., Bavinck J.N. Ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol. 2008;43:353–360.
63. Jackson S., Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene. 2000;19:592–598.
64. Bouwes Bavinck J.N., Neale R.E., Abeni D. et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res. 2010;70:9777–9786.
65. Proby C.M., Harwood C.A., Neale R.E. et al. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant. 2011;11:1498–1508.
66. Shamanin V., zur Hausen H., Lavergne D. et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients [see comments]. J Natl Cancer Inst. 1996;88:802–811.
67. Weissenborn S.J., Nindl I., Purdie K. et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 2005;125:93–97.
68. Arron S.T., Ruby J.G., Dybbro E., Ganem D., Derisi J.L. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol. 2011;131:1745–1753.
69. Lowy D.R., Schiller J.T. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167–1173.
70. Schiller J.T., Castellsague X., Villa L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26S:K53–K61.
71. Brown D.R., Kjaer S.K., Sigurdsson K. et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926–935.
72. Herrero R., Wacholder S., Rodriguez A.C. et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov. 2011;1:408–419.
73. Wheeler C.M., Castellsague X., Garland S.M. et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100–110.
74. Chaturvedi A.K. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46:S20–S26.
75. Peres J. For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst. 2011;103:360–362.
76. Pastrana D.V., Gambhira R., Buck C.B. et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005;337:365–372.
77. Roden R.B., Ling M., Wu T.C. Vaccination to prevent and treat cervical cancer. Hum Pathol. 2004;35:971–982.
78. Yuan H., Estes P.A., Chen Y. et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol. 2001;75:7848–7853.
79. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218–223.
80. Burkitt D. Determining the climatic limitations of a children’s cancer common in Africa. Br Med J. 1962;2:1019–1023.
81. Epstein M.A., Barr Y.M. Cultivation in vitro of human lymphoblasts from Burkitt’s malignant lymphoma. Lancet. 1964;1:252–253.
82. Epstein M.A., Achong B.G., Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1:702–703.
83. Henle G., Henle W., Diehl V. Relation of Burkitt tumor associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci U S A. 1968;59:94–101.
84. Longnecker R., Kieff E., Cohen J.I. Epstein-Barr virus. In: Knipe D.M., Howley P.M., eds. Fields Virology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013:1898–1959.
85. Mann R.B., Bernard C.W. Burkitts tumor: lessons from mice, monkeys, and man. Lancet. 1979;2:84.
86. Moss D.J., Burrows S.R., Catelino D.J. et al. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and nonendemic regions of Papua New Guinea. Int J Cancer. 1983;31:727–732.
87. Manolov G., Manolova Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature. 1972;237:33–34.
88. Lenoir G.M., Taub R. Chromosomal translocations and oncogenes in Burkitt’s lymphoma. In: Goldman J.M., ed. Leukaemia and Lymphoma Research: Genetic Rearrangements in Leukaemia and Lymphoma. London:; 1986:152–172.
89. Murray R.J., Kurilla M.G., Brooks J.M. et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implication for the immune control of EBV-positive malignancies. J Exp Med. 1992;176:157–168.
90. zur Hausen H., Schulte-Holthausen H., Klein G. et al. EBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature. 1970;228:1056–1058.
91. Andersson-Anvret M., Forsby N., Klein G., Henle W. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer. 1977;20:486–494.
92. Raab-Traub N., Flynn K., Pearson G. et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer. 1987;39:25–29.
93. Pagano J.S. Epstein-Barr virus transcription in nasopharyngeal carcinoma. J Virol. 1983;48:580–590.
94. Weiss L., Movahed L., Warnke R., Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med. 1989;320:502–506.
95. Weiss L., Strickler J., Warnke R., Purtilo D., Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathol. 1987;129:86–91.
96. Herbst H., Dallenbach F., Hummel M. et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A. 1991;88:4766–4770.
97. Herbst H., Niedobitek G., Kneba M. et al. High incidence of Epstein-Barr virus genomes in Hodgkin’s disease. Am J Pathol. 1990;137:13–18.
98. Pallesen G., Hamilton-Dutoit S., Rose M., Young L. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet. 1991;337:320–322.
99. Hamilton-Dutoit S.J., Pallesen G. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin’s lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. Am J Pathol. 1992;140:1315–1325.
100. Chang Y., Cesarman E., Pessin M.S. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–1869.
101. Ganem D. A.I.D.S. Viruses, cytokines and Kaposi’s sarcoma. Curr Biol. 1995;5:469–471.
102. Ensoli B., Barillari G., Gallo R.C. Pathogenesis of AIDS-associated Kaposi’s sarcoma. Hematol Oncol Clin North Am. 1991;5:281–295.
103. Sarid R., Olsen S.J., Moore P.S. Kaposi’s sarcoma-associated herpesvirus: epidemiology, virology and molecular biology. Adv Virus Res. 1999;52:139–232.
104. Cesarman E., Moore P.S., Rao P.H., Inghirami G., Knowles D.M., Chang Y. In vitro establishment and characterization of two AIDS-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi’s sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 1995;86:2708–2714.
105. Renne R., Zhong W., Herndier B., McGrath M., Kedes D., Ganem D. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in a cultured B cell lymphoma line. Nat Med. 1996;2:342–346.
106. Moore P.S., Chang Y. Antiviral activity of tumor-suppressor pathways: clues from molecular piracy by KSHV. Trends Genet. 1998;14:144–150.
107. Damania B., Cesarman E. Kaposi’s sarcoma-associated herpesvirus. In: Knipe D.M., Howley P.M., eds. Fields Virology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013:2080–2128.
108. Beasley R.P., Lin C.C., Hwang L., Chien C. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–1133.
109. Evans A.A., Chen G., Ross E.A., Shen F.M., Lin W.Y., London W.T. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002;11:369–376.
110. Seeger C., Zoulim F., Mason W.S. Hepadnaviruses. In: Knipe D.M., Howley P.M., eds. Fields Virology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013:2185–2221.
111. Summers J., Mason W.S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 1982;29:403–415.
112. Hansen L.J., Tennant B.C., Seeger C., Ganem D. Differential activation of myc gene family members in hepatic carcinogenesis by closely related hepatitis B virus. Mol Cell Biol. 1993;13:659–667.
113. Koike K., Moriya K., Iino S. et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology. 1994;19:810–819.
114. Chisari F.V., Klopchin K., Moriyama T. et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell. 1989;59:1145–1156.
115. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immun. 1995;13:29–60.
116. Nakamato Y., Guidotti L.G., Kuhlen C.V., Fowler P., Chisari F.V. Immune pathogenesis of hepatocellular carcinogenesis. J Exp Med. 1998;188:341–350.
117. Beasley R.P. Hepatitis B virus—the major etiology of the hepatocellular carcinoma. Cancer. 1988;61:1942–1956.
118. Chang M.H., You S.L., Chen C.J. et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348–1355.
119. Donato F., Boffetta P., Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998;75:347–354.
120. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362.
121. Kuo G., Choo Q.L., Alter H.J. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362–364.
122. Ray S.C., Bailey J.R., Thomas D.L. Hepatitis C virus. In: Knipe D.M., Howley P.M., eds. Fields Virology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013:795–824.
123. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77:7415–7419.
124. Poiesz B.J., Ruscetti F.W., Reitz M.S., Kalyanaraman V.S., Gallo R.C. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukemia. Nature. 1981;294:268–271.
125. Yoshida M., Miyoshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in disease. Anat Rev. 1982;117:532.
126. Kalyanaraman V.S., Sarngadharan M.G., Robert-Guroff M., Miyoshi I., Golde D., Gallo R.C. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 1982;218:571–573.
127. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia-clinical and hematological features of 16 cases. Blood. 1977;50:481–492.
128. Hinuma T., Nagata K., Misoka M. et al. Adult T cell leukemia: antigen in an ATL cell line and detection of antibodies of the antigen in human sera. Proc Natl Acad Sci U S A. 1981;78:6476–6480.
129. Fujii M., Matsuoka M. Human T-cell leukemia virus types 1 and 2. In: Knipe D.M., Howley P.M., eds. Fields Virology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013:1474–1501.
130. Greene W.C., Leonard W.J., Wano Y. et al. Trans-activator gene of HTLV-11 induces IL-2 cellular gene expression. Science. 1986;232:877–880.
131. Suzuki T., Hirai H., Murakami T., Yoshida M. Tax protein of HTLV-1 destabilizes the complexes of NF-kappa B and I kappa B-alpha and induces nuclear translocation of NF-kappa B for transcriptional activation. Oncogene. 1995;10:1199–1207.
132. Hirai H., Suzuki T., Fujisawa J., Inoue J., Yoshida M. Tax protein of human T-cell leukemia virus type I binds to the ankyrin motifs of inhibitory factor kappa B and induces nuclear translocation of transcription factor NF-kappa B proteins for transcriptional activation. Proc Natl Acad Sci U S A. 1994;91:3584–3588.
133. Suzuki T., Kitao S., Matsushime H., Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J. 1996;15:1607–1614.
134. Pise-Masison C.A., Brady J.N. Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. Front Biosci. 2005;10:919–930.
135. Kawata S., Ariumi Y., Shimotohno K. p21(Waf1/Cip1/Sdi1) prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded tax. J Virol. 2003;77:7291–7299.
136. Kao S.Y., Lemoine F.J., Marriott S.J. Suppression of DNA repair by human T cell leukemia virus type 1 Tax is rescued by a functional p53 signaling pathway. J Biol Chem. 2000;275:35926–35931.
137. Liu B., Liang M.H., Kuo Y.L. et al. Human T-lymphotropic virus type 1 oncoprotein tax promotes unscheduled degradation of Pds1p/securin and Clb2p/cyclin B1 and causes chromosomal instability. Mol Cell Biol. 2003;23:5269–5281.
138. Satou Y., Yasunaga J., Yoshida M., Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A. 2006;103:720–725.
139. McClure M.O., Weiss R.A. Human immunodeficiency virus and related viruses. Curr Top AIDS. 1987;1:95–117.
140. Pinching A., Weiss R.A. AIDS and the spectrum of HTLV-III/LAV infection. Int Rev Exp Pathol. 1986;28:1–44.
141. Poulin D.L., DeCaprio J.A. Is there a role for SV40 in human cancer? J Clin Oncol. 2006;24:4356–4365.
142. Shah K.V. SV40 and human cancer: a review of recent data. Int J Cancer. 2007;120:215–223.
143. Lopez-Rios F., Illei P.B., Rusch V., Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet. 2004;364:1157–1166.
144. Manfredi J.J., Dong J., Liu W.J. et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res. 2005;65:2602–2609.
145. Feng H., Shuda M., Chang Y., Moore P.S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–1100.
146. Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972;105:107–110.
147. Tolstov Y.L., Pastrana D.V., Feng H. et al. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer. 2009;125:1250–1256.
148. Schowalter R.M., Pastrana D.V., Pumphrey K.A., Moyer A.L., Buck C.B. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe. 2010;7:509–515.
149. DeCaprio J.A., Imperiale M.J., Major E.O. Polyomaviruses. In: Knipe D.M., Howley P.M., eds. Fields Virology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013:1633–1661.
150. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–1315.
151. Marshall B.J., Armstrong J.A., McGechie D.B., Glancy R.J. Attempt to fulfil Koch’s postulates for pyloric. Campylobacter. Med J Aust. 1985;142:436–439.
152. Tomb J.F., White O., Kerlavage A.R. et al. The complete genome sequence of the gastric pathogen. Helicobacter pylori. Nature. 1997;388:539–547.
153. Hatakeyama M. Helicobacter pylori CagA—a bacterial intruder conspiring gastric carcinogenesis. Int J Cancer. 2006;119:1217–1223.
154. Tsuji S., Kawai N., Tsujii M., Kawano S., Hori M. Review article: inflammation-related promotion of gastrointestinal carcinogenesis—a perigenetic pathway. Aliment Pharmacol Ther. 2003;18(suppl 1):82–89.
155. zur Hausen H. Infections Causing Human Cancer. Weinheim, Germany: Wiley-VCH; 2006.